-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Total mesorectal resection following neoadjuvant chemotherapy (nCRT) is the current standard of care for patients with locally advanced rectal cancer (LARC); however, treatment response varies from no tumor regression to pathological complete response ( pCR) are very different
Although MRI is the modality of choice for assessing and assessing nCRT response prior to initial treatment in patients with rectal cancer, intuitive assessment of pCR remains challenging due to relatively little consensus on the assessment of nCRT response by MRI
Recently, a study published in the journal Radiology established a radiomics model using MRI (T2-weighted and DWI) as a potential imaging metric for predicting pCR after nCRT in LARC patients and evaluated their diagnostic performance based on qualitative assessments by radiologists.
This retrospective study included patients with LARC (clinical stage T3 or higher, positive nodule status, or both) who underwent MRI and elective resection after nCRT between January 2009 and December 2018.
Of the 898 patients, 189 (21%) achieved pCR
Receiver operating characteristic curve analysis of radiomic scores predicting pathological complete response in (A) training and (B) testing groups
Receiver operating characteristic curve analysis of radiomic scores predicting pathological complete response in (A) training and (B) testing groups
Original source:
Original source:Jaeseung Shin, Nieun Seo, Song-Ee Baek.
Jaeseung Shin, Nieun Seo, Song-Ee Baek.
MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy.
DOI: 10.
1148/radiol.
211986.
Leave a comment here